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Background: Infants born extremely preterm are at high risk of dying or suffering from severe brain injuries.
Treatment guided by monitoring of cerebral oxygenation may reduce the risk of death and neurologic
complications. The SafeBoosC III trial evaluates the effects of treatment guided by cerebral oxygenation monitoring
versus treatment as usual. This article describes the detailed statistical analysis plan for the main publication, with
the aim to prevent outcome reporting bias and data-driven analyses.
Methods/design: The SafeBoosC III trial is an investigator-initiated, randomised, multinational, pragmatic phase III
trial with a parallel group structure, designed to investigate the benefits and harms of treatment based on cerebral
near-infrared spectroscopy monitoring compared with treatment as usual. Randomisation will be 1:1 stratified for
neonatal intensive care unit and gestational age (lower gestational age (< 26 weeks) compared to higher
gestational age (≥ 26 weeks)). The primary outcome is a composite of death or severe brain injury at 36 weeks
postmenstrual age. Primary analysis will be made on the intention-to-treat population for all outcomes, using
mixed-model logistic regression adjusting for stratification variables. In the primary analysis, the twin intra-class
correlation coefficient will not be considered. However, we will perform sensitivity analyses to address this. Our
simulation study suggests that the inclusion of multiple births is unlikely to significantly affect our assessment of
intervention effects, and therefore we have chosen the analysis where the twin intra-class correlation coefficient will
not be considered as the primary analysis.
Discussion: In line with the Declaration of Helsinki and the International Conference on Harmonization Good
Clinical Practice guidelines, we have developed and published this statistical analysis plan for the SafeBoosC III trial,
prior to any data analysis.
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Trial registration: ClinicalTrials.org, NCT03770741. Registered on 10 December 2018.
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analysis planBackground
Extremely preterm infants carry a high risk of death,
with a mortality rate up to 25% [1, 2]. Furthermore,
about 20% suffer from long-term neurodevelopmental
impairment such as cerebral palsy or low intelligence
quotient [2, 3]. Psychomotor impairment is a major
cause of reduced quality of life and increased costs of
medical care, rehabilitation, and special education in this
population [4]. Low intelligence quotient affects all as-
pects of life. With increasing life expectancy, these com-
bined prematurity-related factors pose a significant
problem.
Hypoxia has been associated with mortality and brain
injury in the preterm population [5]. In the SafeBoosC II
trial, cerebral near-infrared spectroscopy (NIRS) monitor-
ing combined with an evidence-based treatment guideline
significantly reduced the burden of hypoxia during the
first days of life in preterm infants [6]. There were also
trends towards reduced occurrence of severe brain injury
and mortality [6]. On the other hand, the incidence of
bronchopulmonary dysplasia and retinopathy of prema-
turity was higher among NIRS-monitored neonates [6].
However, SafeBoosC II was not powered to demonstrate
effects on these outcomes; thus, high-certainty evidence of
clinical benefit and harm in extremely preterm infants is
lacking [7]. We therefore plan a larger phase III trial, Safe-
BoosC III, powered to demonstrate the potential benefits
and harms of treatment based on cerebral NIRS monitor-
ing compared with treatment as usual on patient-centred
clinical outcomes. As the SafeBoosC III trial will be con-
ducted in compliance with the Declaration of Helsinki in
its latest form and the International Conference on
Harmonization Good Clinical Practice guidelines [8], we
have developed this detailed statistical analysis plan. We
believe this will decrease the risk of outcome reporting
bias and data-driven analyses.Methods/design
Trial overview
SafeBoosC III is an investigator-initiated, open-label,
randomised, multinational, pragmatic phase III clinical
trial with a parallel group design. The primary objective
is to evaluate the benefits and harms of treatment based
on cerebral NIRS monitoring during the first 72 postna-
tal hours in extremely preterm infants [9], compared
with treatment and monitoring as usual, to reduce cere-
bral hypoxia [10]. The hypothesis is that treatment basedon NIRS monitoring for extremely preterm infants during
the first 72 h of life will result in a reduction in death or se-
vere brain injury assessed at 36 weeks postmenstrual age.
We plan to test for superiority of the experimental inter-
vention compared with the control group for only the pri-
mary outcome, since exploratory outcomes will only be
hypothesis generating (see ‘Level of significance’). Infants
will be randomised with an allocation ratio of 1:1 to either
the experimental group or the control group stratified for
neonatal intensive care unit (NICU) and gestational age
(lower gestational age (< 26weeks) compared to higher ges-
tational age (≥ 26 weeks)). Details of the randomisation
method are held securely in the statistics master file. Infants
in the experimental group will start cerebral NIRS monitor-
ing as close to birth as possible, but at least within 6 h of
birth, and receive treatment based on NIRS monitoring
during the first 72 h of life (Fig. 1). These treatments will
follow an evidence-based treatment guideline [11]. Infants
in the control group will not receive cerebral NIRS moni-
toring and will be monitored and treated according to local
guidelines and practices (i.e. treatment as usual). Due to the
nature of NIRS, it is difficult to blind the clinical staff or the
parents of the trial participants.
Three different consent methods may be used in this
trial: prior informed consent (prenatal and postnatal);
deferred consent; and prior assent/‘opt-out’. The trial
will be conducted at more than 50 centres across up to
20 countries (16 European countries, India, China, and
the USA), and the protocol will be published in an inter-
national peer-reviewed journal [10].
The SafeBoosC III trial is registered at ClinicalTrials.org
(NCT03770741) and is compliant with the Declaration of
Helsinki in its latest form and with the International Con-
ference on Harmonization Good Clinical Practice. The
trial will be approved by relevant authorities, including re-
search ethics boards and data protection agencies, in all
participating centres. The progression of the trial can be
followed at www.safeboosc.eu. This statistical analysis plan
has been written and submitted before randomisation
commences and all data analysis for the main publication
will be compliant to this plan.Outcomes
Primary outcome
The primary outcome is a composite of either death or
severe brain injury. Severe brain injuries will be defined
as grade III or IV cerebral haemorrhage (Papile’s
Fig. 1 Trial flow diagram. BPD bronchopulmonary dysplasia, NEC necrotising enterocolitis, NICU neonatal intensive care unit, ROP retinopathy
of prematurity
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[2], cerebellar haemorrhage, post-haemorrhagic ven-
tricular dilatation, or cerebral atrophy. These cerebraloutcomes will be reported as detected on any one of a
series of cranial ultrasound scans that are routinely per-
formed in these infants.
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but diagnosis and classification of brain injury and entry
of this information into electronic case report forms will
be conducted by a clinician blinded to group allocation.
Exploratory outcomes
 A count of the presence of the three major neonatal
morbidities associated with neurodevelopmental
impairment later in life [13]: bronchopulmonary
dysplasia (defined below), retinopathy of prematurity
(as defined below), and severe brain injury as
defined in the primary outcome (i.e. a value of 0, 1,
2, or 3)
 Bronchopulmonary dysplasia defined as oxygen or
ventilator/continuous positive airway pressure
requirement at 36 weeks’ postmenstrual age
 Retinopathy of prematurity stage 3 and above at any
time prior to 36 weeks’ postmenstrual age
 Late-onset sepsis (> 72 h after birth) defined as
treatment with antibiotics for at least 5 days
 Necrotising enterocolitis stage 2 or higher using the
modified Bell’s staging system [14] and/or focal
intestinal perforation at any time up until 36 weeks’
postmenstrual age
Outcome assessment time point
All outcomes will be assessed at 36 weeks postmenstrual
age.
Sample size
We have calculated our sample size with an α of 5%, a
power of 90%, and a ratio of experimental trial partici-
pants to control trial participants of 1:1. The primary
outcome is the composite outcome of death or severe
brain injury. Sample size calculations were performed
for the composite outcome and not for the individual
components.
Calculated from the 2009 dataset from the EuroNe-
oNet project [15] the mortality was 33% and severe
intracranial haemorrhage was observed in 15%. In the
SafeBoosC II trial, the proportion of trial participants in
the control group with the same composite primary out-
come was approximately 34% and in the experimental
group was 26% [6]. Mortality was 24% in the control
group versus 13% in the experimental group and the
proportion of infants with severe brain injury was 23%
versus 13% [6].
Based on the aforementioned, a total of 1600 infants
— 800 infants randomised to the experimental group
and 800 infants to the control group — would be re-
quired to demonstrate a reduction of the primary out-
come from 34.0% to 26.5%, with an α of 5% and a power
of 90%. This corresponds to a 22% relative risk reductionor a 7.5% absolute risk reduction. We consider this a
clinically relevant and important benefit, since mortality
is of direct patient relevance and since surviving infants
with severe brain injury (about 25%) are at approxi-
mately 40% risk of moderate-to-severe neurodevelop-
mental impairment [16]. This absolute risk reduction
corresponds to a ‘number-needed to treat’ of 15 infants
and, if our null hypothesis is rejected, is likely to influ-
ence clinical practice.
Power calculations for exploratory outcomes
For the exploratory outcomes, we have performed power
calculations as presented in Table 1.
Assuming a mean major neonatal morbidity count
(bronchopulmonary dysplasia, retinopathy of prematur-
ity, and severe brain injury) of 0.62 among extremely
preterm infants [17], with a standard deviation of 0.80
and a relative risk increase or decrease of 20% in the ex-
perimental group, we will be able to detect this differ-
ence between the experimental and control group with
87% power at a 5% significance level (Table 1).
Assuming a 40% prevalence of bronchopulmonary dys-
plasia among extremely preterm infants [18] and a rela-
tive risk decrease or increase of 20% in the experimental
group, we will be able to detect this difference between
the experimental and control group with 89% power at a
5% significance level (Table 1).
Assuming a 13% prevalence of stage 3 and above retin-
opathy of prematurity among extremely preterm infants
and a relative risk decrease or increase of 30% in the ex-
perimental group [7], we will be able to detect this dif-
ference between the experimental and control groups
with 68% power at a 5% significance level (Table 1).
Assuming a 40% prevalence of late-onset sepsis in the
control group [1], defined as treatment with antibiotics
for at least 5 days, and a 20% relative risk decrease or in-
crease in the experimental group, we will be able to de-
tect this difference between the experimental and
control groups with 91.2% power at a 5% significance
level (Table 1).
Assuming an 11% prevalence of stage 2 and 3 necrotis-
ing enterocolitis among extremely preterm infants and a
17% relative risk decrease or increase in the experimen-
tal group, as is the estimate from existing trials [7], we
will be able to detect this difference between the experi-
mental and control groups with 23% power at a 5% sig-
nificance level (Table 1).
Assessment of outcomes and additional clinical variables
There will be three time points for data collection: at
randomisation (from 0 to 6 h after birth); at the end of
the intervention period (72 h of life); and at 36 weeks
postmenstrual age. Data on feasibility will be assessed at
randomisation. At the end of the intervention period,
Table 1 Overview of power calculations for exploratory outcomes
Outcome Assumption on prevalence in background population (%) Assumption on risk increase or decrease (%) Power (%)
Major neonatal morbidities 0.62 (0.8)a 20 87
Bronchopulmonary dysplasia 40 20 89
Retinopathy of prematurity 13 30 68
Late-onset sepsis 40 20 91.2
Necrotising enterocolitis 11 17 23
For definition of outcomes, see ‘Outcomes’. All power calculations have been made with a 5% significance level
aPresented as mean count (standard deviation)
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toring and safety parameters. As mentioned, all out-
comes will be assessed at 36 weeks postmenstrual age.
Severe brain injury diagnosis and classification data will
be collected either by neonatologists assessing all cranial
ultrasound scans performed up until 36 weeks post-
menstrual age or by reading radiologists’ descriptions of
these scans. This assessment and data entry will be con-
ducted by a person blinded to group allocation. No
long-term follow-up has been formally planned. How-
ever, we encourage clinical sites to conduct long-term
follow-up, and we have therefore developed an appendix
in the protocol (see full protocol at www.safeboosc.eu)
describing possible outcomes for later follow-up studies
and how these could be conducted. Currently, no proto-
col for such an ancillary study has been developed.
Explanatory variables
Additional clinical data on trial participants will be
drawn from clinical files, in order to compare character-
istics between intervention groups. Data will be drawn
from clinical records at 72 h of age and 36 weeks post-
menstrual age. These data consist of a subset of explana-
tory variables, with the majority usually being reported
to the neonatal network databases, such as Vermont Ox-
ford Network [19]. These data will be presented in a
table in the main publication (see Table 2). Tests of stat-
istical significance will not be undertaken for explana-
tory variables. Categorical data will be summarised by
numbers and percentages. Continuous data will be sum-
marised by mean and standard deviation if normally dis-
tributed or by median and interquartile range if non-
normally distributed.
Safety
We will report the total number of serious adverse reac-
tions, as defined in the protocol [10] for each group, as
well as the total number of participants who experienced
one or more serious adverse reactions in each group.
We will also report the total number of serious adverse
events, as defined in the protocol [10] in each group, as
well as the number of participants who experienced one
or more serious adverse events in each group.Level of significance
The thresholds for significance will be assessed accord-
ing to a 5-point procedure, suggested by Jakobsen et al.
[20]. We will calculate and report confidence intervals
and exact p-values for the primary and exploratory out-
comes. All confidence intervals presented will be 95%
and two-sided. A p-value of less than 0.05 will be used
as the threshold for statistical significance for our pri-
mary outcome, since this value was used as the accept-
able risk of type I error in our sample size estimation
(see ‘Sample size’) and since we plan to report on only
one primary outcome. However, in our interpretation of
the results, we will assess any effect of the experimental
intervention according to the point estimate taking into
consideration the confidence interval as well as interven-
tion effects on other outcomes [21]. All remaining out-
come results will only be considered hypothesis-
generating. Since our primary conclusion will be based
on one outcome result at one time point, we will limit
problems associated with multiple testing, due to mul-
tiple outcome comparisons [22].
Secondly, we will calculate and report the Bayes factor
[23] for the primary outcome [24]. The Bayes factor is the
ratio between the probability of the results given that the
null hypothesis (H0) is true divided by the probability of
the results given that the alternative hypothesis (HA) is
true [23]. In the SafeBoosC III trial, the alternative hypoth-
esis is that the treatment effect is the effect that was used
for the sample size calculation: a 22% relative risk reduc-
tion in the experimental group. By calculating the Bayes
factor, we will be able to interpret the results of the pri-
mary outcome in relation to former trial results [6].
Thirdly, Lan–DeMets monitoring boundaries will be
used to adjust the threshold for statistical significance at
each interim analysis to judge whether the trial should
be terminated early [25]. This is done in order to avoid a
false rejection of the null hypothesis based on insuffi-
cient sample sizes [26]. The trial will not be stopped pre-
maturely due to futility. The fourth step in the five-step
procedure by Jakobsen et al., regarding adjustment of p-
values based on multiple testing of the primary outcome,
is not applicable to our trial, since we have a single pri-
mary outcome [20].
Table 2 Explanatory variables divided by experimental group and control group participants
Variables Experimental group (n) Control group (n)
At randomisation
Birth weight (g)
Gestational age (weeks)
Apgar 1 min (1–10)
Apgar 5 min (1–10)
Gender
Male (%)
Female (%)
At 72 h of age
Age when NIRS monitoring started (h)a N/A
Stopping NIRS monitoring before end of monitoring period (%)a N/A
Parents discontinuing trial participation (%)
Changes in treatment due to cerebral hypoxia (%)a N/A
Registered cardiovascular support treatment (%)a N/A
Type of NIRS device useda
INVOS (%)
NIRO (%)
Fore-Sight (%)
Sensmart (%)
O3 (%)
Egos (%)
Oxyprem (%)
Other (%)
N/A
Cerebral NIRS monitoring despite being in control group (%)b N/A
Surfactant therapy (%)
Severe adverse reactions (%)
At 36 weeks postmenstrual age
Major congenital anomaly (%)
Mechanical ventilation (%)
Time with mechanical ventilation (days)
Patent ductus arteriosus (%)
Weight (g)
Early cranial ultrasound scan (%)
Late cranial ultrasound scan (%)
Data expressed as median (range) for continuous variables, and numbers (percentage) for dichotomous variables
N/A not applicable, NIRS near-infrared spectroscopy
aVariables only relevant for experimental group participants
bVariables only relevant for control group participants
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dence intervals into consideration when making study
conclusions [21]. Clinical significance will be assessed by
calculating the number needed to treat based on the ab-
solute risk reduction data. Based on the results from the
phase II trial, we expect an absolute risk reduction of
7.5%, which corresponds to a number needed to treat of
15 (see ‘Sample size’) [6].
Interim analyses
One pre-planned interim analysis will be conducted after
one-third of trial participants have been randomised.
The timing and prevalence of additional interim analyses
will be decided solely by the data monitoring and safetycommittee members. The data monitoring and safety
committee will make recommendations to the steering
group to continue, change, hold, or terminate the trial.
This recommendation will be based primarily on safety
considerations and will be guided by statistical monitor-
ing guidelines, defined in the data monitoring and safety
committee charter. The data monitoring and safety com-
mittee will be provided with the following data from the
Coordinating Data Centre: number of participants ran-
domised, number of participants per intervention group
(0,1), number of participants stratified per stratification
variable per intervention group (0,1), and number of
events (primary outcome, SAEs, and SARs) in the two
groups. Based on the evaluations of these outcomes, the
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whether they want further data from the Coordinating
Data Centre, and when next to perform analyses of data.
Based on the analyses of the safety variables, the data
monitoring and safety committee is suggested to use
Lan–DeMets sequential monitoring boundaries, based
upon a relative risk increase of 100% of mortality from
25% to 50%. For any of the other safety outcomes, the
statistical limit to guide its recommendations regarding
early termination of the trial for harms is recommended
also to be conservative.
Handling of missing data
Missing data will be minimised by performing repeated
monitoring of data entry into electronic case report
forms. In this way, we will be able to monitor the extent
of missing data and intervene if necessary. Hence, we do
not anticipate that there will be any significant number
of missing values. However, we will consider using mul-
tiple imputation and present best–worst and worst–best
case scenarios if it is not valid to ignore missing data ac-
cording to the standards reported by Jakobsen et al. [27].
When using best–worst and worst–best case scenarios,
we will assess the potential range of impact of the miss-
ing data for the trial results [27]. In the ‘best–worst’ case
scenario, it is assumed that all patients lost to follow-up
in the experimental group have had a beneficial out-
come, and all those with missing outcomes in the con-
trol group have had a harmful outcome [27]. Conversely,
in the ‘worst–best’ case scenario, it is assumed that all
patients who were lost to follow-up in the experimental
group have had a harmful outcome, and that all those
lost to follow-up in the control group have had a benefi-
cial outcome [27].
As recommended, we will describe reasons why out-
come data are missing in the main study manuscript
[28]. Furthermore, we will compare explanatory variables
between all participants randomised to intervention
groups (including those with missing outcomes), and
also between participants in the intervention groups,
where outcomes are reported. This is done to identify
imbalances between groups due to missing outcome
data [29].
Twins and their intra-cluster correlation
In extremely preterm populations, 30% of births may be
twins [6], which poses a potential problem for statistical
analyses as the outcomes among pairs of twins are po-
tentially correlated [30]. In the SafeBoosC III trial, mul-
tiple birth infants will be randomised as a ‘pair’ or a
‘group’ (i.e. all siblings will be allocated to the same
intervention group). In centres where only one or two
cerebral monitoring devices are available, it may not be
possible to include all infants from multiple births. Thus,only one of a pair or only one or two infants of triplets
may be included. The sibling(s) enrolled in the trial will
be the one(s) born last. In the SafeBoosC II trial, the
intra-class correlation coefficient (ICC) of the burden of
hypoxia within pairs of twins was negligible. The ICC
for various binary outcomes has been estimated in a pre-
vious study: ICC for death before discharge was esti-
mated as 0.00 (95% confidence interval (CI) –0.04 to
0.02) and for intraventricular haemorrhage grade 3 or 4
as − 0.01 (95% CI − 0.05 to 0.01) [31]. These values cor-
relate to a design effect very close to 1 [31]. Therefore,
in the primary analysis, we will analyse twin data as in-
dependent observations. However, due to the possibility
that the correlation between the primary outcome within
multiple births will interfere with the estimation of the
treatment effect [32], and particularly the assessment of
estimation uncertainty, we will perform a sensitivity ana-
lysis, taking this effect into consideration. This sensitivity
analysis will be performed using the generalised estimat-
ing equation (GEE) approach utilising an exchangeable
covariance matrix with site (NICU) and stratification
variables as fixed effects. The results of both primary
outcome analyses will be presented and discrepancies
between the two analyses discussed in the final publica-
tion. Furthermore, we will calculate, report, and discuss
the ICC for the primary outcome.Stratification
We will use site (NICU) and gestational age (lower ges-
tational age (< 26 weeks) compared to higher gestational
age (≥ 26 weeks)) as stratification variables in the ran-
domisation. Analyses for all outcomes will be adjusted
for these stratification variables [33–35].Assessment of underlying statistical assumptions
For all regression analyses, we will test for major in-
teractions between each covariate and the interven-
tion variable. We will, in turn, include each possible
first-order interaction between included covariates
and the intervention variable. For each combination,
we will test whether the interaction term is significant
and assess the effect size. We will only consider that
there is evidence of an interaction if the interaction is
statistically significant after Bonferroni-adjusted
thresholds (0.05 divided by number of possible inter-
actions) and if the interaction shows a clinically sig-
nificant effect. If it is concluded that the interaction
is significant, we will be presenting an analysis separ-
ately for each (e.g. for each site if there is significant
interaction between the trial intervention and ‘site’)
and an overall analysis including the interaction term
in the model.
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dichotomous outcomes
We will assess whether the deviance divided by the de-
grees of freedom is significantly larger than 1 to assess
for relevant overdispersion, and in this case consider
using a maximum likelihood estimate of the dispersion
parameter. To avoid analytical problems with either zero
events or problems such as all participants dying at a
given site, we have only included sites planning to ran-
domise a sufficient number of participants. However, we
cannot exclude the risk that some sites might have prob-
lems with recruitment. We will, by checking whether the
number of participants is larger than 10 (rule of thumb)
per site, pool the data from small sites if the number of
participants is too low.
Statistical analyses
Analyses will be made on the intention-to-treat popula-
tion for all outcomes, since this method maintains base-
line comparability of the intervention groups [29]. The
intention-to-treat population will include all randomised
patients, regardless of missing data, lost to follow-up or
adherence to the intervention.
In our primary analysis, we will analyse dichotomous
outcomes using mixed-effect logistic regression and
count data using mixed-effect linear regression with ro-
bust standard errors. In all regression models, ‘site’ will
be included as a random effect. The remaining stratifica-
tion variables (age and intervention groups) will be in-
cluded as fixed effects. The sensitivity analysis
accounting for the possible correlation between twins is
described in ‘Twins and their intra-cluster correlation’.
As an additional sensitivity analysis, we will perform a
per-protocol analysis, only including participants who
had no missing data, were not lost to follow-up, and ad-
hered to the intervention. Adherence to the intervention
is defined as continuous cerebral oxygenation monitor-
ing during the first 72 h of life or until death.
We will, in a secondary analysis, analyse the results
using random-effects meta-analysis [36].
All outcomes will be analysed collectively since the
follow-up time is identical.
Data management
The data management plan has been described in the
protocol paper [10].
CONSORT flow diagram
The main publication will include a Consolidated Stan-
dards of Reporting of Randomised Trials (CONSORT)
flow diagram, following the CONSORT 2010 Statement
[37]. This will be used to summarise the number of pa-
tients who were randomised, allocated to the experimen-
tal and control groups, adhered and unadhered to theintervention, lost to follow-up (including parental and
physician withdrawal), randomised and included in the
primary analysis, and randomised and excluded from the
primary analysis.
Withdrawal
Parents will be able to withdraw consent at any time
during the trial. However, data on participants up until
the day of withdrawal will be used and participants will
be part of the intention-to-treat population and analysis.
Blinding of statisticians
All data managers, statisticians, and those drawing con-
clusions will be blinded to treatment allocation. Two
blinded statisticians connected to The Copenhagen Trial
Unit will independently perform all statistical analyses
and the two statistical reports will be published as sup-
plemental material. Discrepancies between the two re-
ports will be discussed by the Steering Committee of the
trial. The two intervention groups will be coded ‘A’ and
‘B’. When comparability between the two independent
analyses have been obtained, two abstracts will be writ-
ten: one assuming ‘A’ is the experimental group and ‘B’
is the control group – and one assuming the opposite.
After the conclusions have been drawn, blinding will be
broken, and the final manuscript will be based on the
correct pre-written abstract.
Simulation of twin scenarios
To explore the potential impact of twin correlation, we
conducted a simulation study to assess potential impact
on power and coverage probabilities of confidence inter-
vals (i.e. does the computed 95% CI contain the true
parameter values with 95% probability). We compared
the naive analysis (primary analysis of the primary out-
come), which ignores twin pairs, to a GEE-based ap-
proach which does account for twin correlation. We did
this by simulating 10,000 trials with sample size and true
parameter values as in the sample size estimation and
varied twin probability and ICC. These results are pre-
sented in Table 3. This simulation study shows that for
a low ICC value or low twin proportion, we can expect
both the naive and GEE analyses to have correct
coverage and equal power. For a high ICC and a high
twin proportion, we can expect the GEE analysis to
retain correct coverage, while the naive analysis will
have decreased coverage; these differences, however,
would be minimal. For high twin proportion and high
ICC values, the effective sample size was reduced,
which as expected implied that the correct analysis
(the GEE) yields a lower power than the intended
90%, albeit only marginally so, and that the coverage
for the naïve analysis was a bit too low.
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This article presents the detailed statistical analysis plan
for the SafeBoosC phase III trial. It has been developed
and submitted prior to any randomisation or data collec-
tion in order to avoid data-driven analyses and outcome
reporting bias. Data will be analysed on the intention-to-
treat population, and multiple imputations will be used
if the proportion of missing data cannot be ignored (see
‘Handling of missing data’). An anonymised dataset re-
garding all outcomes will be uploaded to a public data-
base to be available for other researchers and peers 6
months after acceptance of the study manuscript.
We plan to report on both primary and exploratory out-
comes in the main publication, but the conclusion will
solely be based on the results of the primary outcome. If
the result is statistically insignificant, based on the 5-point
procedure by Jakobsen et al. [20], we will conclude that
there is no significant difference between the intervention
and treatment as usual (see ‘Level of significance’).
Dealing with multiple analyses
Planning multiple analyses on a primary outcome has
the potential to increase the risk of type I errors, due to
multiple testing [38]. If it is predefined that a significant
difference between the experimental and control groups
on any one of the primary outcome analyses is sufficientTable 3 Simulation study to assess power and coverage probabilitie
ICC Proportion of
twins
Power of naive
analysis
Power of GEE
analysis
C
an
0 0.1 0.91 0.91 0.
0 0.2 0.91 0.91 0.
0 0.3 0.90 0.90 0.
0 0.4 0.90 0.90 0.
0.01 0.1 0.91 0.91 0.
0.01 0.2 0.90 0.90 0.
0.01 0.3 0.90 0.90 0.
0.01 0.4 0.91 0.90 0.
0.03 0.1 0.90 0.90 0.
0.03 0.2 0.91 0.91 0.
0.03 0.3 0.90 0.90 0.
0.03 0.4 0.90 0.90 0.
0.13 0.1 0.90 0.90 0.
0.13 0.2 0.90 0.89 0.
0.13 0.3 0.90 0.89 0.
0.13 0.4 0.90 0.88 0.
0.2 0.1 0.90 0.90 0.
0.2 0.2 0.90 0.89 0.
0.2 0.3 0.90 0.88 0.
0.2 0.4 0.89 0.87 0.
GEE generalised estimating equation, ICC intra-class coefficientto declare superiority of a given intervention, one would
have to correct for multiple testing by decreasing the α
value [22, 39]. On the other hand, planning that all pri-
mary outcome analyses must show significant benefit of
the intervention to declare superiority has the potential
to increase the risk of type II errors, due to insufficiently
powered analyses [40]. Hence, by only planning one ana-
lysis for the primary outcome and by defining additional
analyses as sensitivity analyses (see ‘Twins and their
intra-cluster correlation’), we have eliminated the type I
and type II error-related issues described above. The
sensitivity analyses on the primary outcome will only be
used to discuss and illustrate the results of the primary
analysis.
Strengths
According to our knowledge, SafeBoosC III will provide
the largest trial, thus far, evaluating the benefits and
harms of treatment guided by cerebral NIRS monitoring
– not only in extremely preterm infants [41] but across
all patient populations [42].
It is an important strength that both the protocol and
statistical analysis plan have been developed and submit-
ted prior to any randomisation or data collection [8, 10].
Furthermore, we have also taken the issue of twins and
their intra-cluster correlation into consideration, bys of confidence intervals of primary outcome
overage probability of naive
alysis
Coverage probability of GEE
analysis
95 0.95
95 0.95
95 0.95
95 0.95
95 0.95
95 0.95
95 0.95
95 0.95
95 0.95
95 0.95
95 0.95
95 0.95
95 0.95
94 0.95
94 0.95
94 0.95
95 0.95
94 0.95
94 0.95
94 0.95
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its potential effect on results (see section on ‘Twins and
their intra-cluster correlation’). To address the potential
impact of twin correlation on our results, we also per-
formed a simulation study, showing that we can expect
the potential impact of twin correlation to be minor.
There is genuine evidence that most randomised clin-
ical trials lack external validity, which is an important
explanation for why multiple interventions proven bene-
ficial in randomised clinical trials are underused in rou-
tine clinical practice [43]. Since SafeBoosC III is an
international trial including multiple sites across differ-
ent countries, limitations to external validity such as dif-
ferent practices between countries and health-care
systems seems less of an issue for external validity. Fur-
thermore, the external validity of our results will also be
described in the main publication, as recommended in
the Consolidated Standards of Reporting of Randomised
Trials guidelines [37].
Limitations
Our methodology also has limitations. Only three of the
five exploratory outcomes are sufficiently powered (80%
power) to show a significant difference between the ex-
perimental and control groups, at a 5% significance level.
If these were categorised as secondary or additional pri-
mary outcomes, we would need to correct for multiple
testing by decreasing the α value using Bonferroni ad-
justments [39]. Therefore, we will not make any clinical
conclusions based on these results. However, we believe
they are important to report and assess since they repre-
sent major neonatal morbidities in our study population
[1, 13, 44].
As thoroughly reported in the SafeBoosC III design
paper [10], it is difficult to blind clinical staff, the infant,
and the parents of the trial participants, which intro-
duces risks of bias [45–48]. This important concern is
discussed in detail in our design paper [10].
As recommended in the European Medicines Agency
Guidelines on Multiplicity Issues in Clinical Trials, the
components of the primary composite outcome (i.e.
death and severe brain injury) will be analysed separately
[49]. However, interpretation of these sub-analyses will
be difficult, since death and severe brain injury as indi-
vidual outcomes are insufficiently powered to show a
real benefit of the intervention.
Trial status
At present, the study protocol has been registered at
www.clinicaltrials.gov (NCT 03770741, registered on 10
December 2018) and has been accepted for publication
[10]. The first participant was randomised on 27 June
2019. Status on recruitment can be accessed at www.
safeboosc.eu.Statistical analysis plan status
Version 1.0 (8 August 2019). This document has been
written based on information available in the protocol
paper [10].
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